检索结果-南通市图书馆

A multicenter uroflowmetry study of healthy women in China

中华医学杂志(英文版) 2024年第10期137卷 1225-1227页

作者： Liu Xiaodong Meng Lingfeng Wang Jiawen Ma Tianming shi benkang Huang Hai Wang Qingwei Chen Min Liao Limin Shen Hong Wei Zhongqing Xiao Yuansong Pan Tiejun Ren Jian Zhang Peng Tian Xiaojun Zhang Yaoguang Department of Urology The Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China Department of Urology General Hospital of Southern Theatre Command Guangzhou Guangdong China Department of Urology General Hospital of Central Theatre Command Wuhan Hubei China Department of Urology China-Japan Friendship Hospital Beijing China Department of Urology Beijing Chao-Yang Hospital Beijing China Department of Urology Peking University Third Hospital Beijing China Department of Urology Beijing Hospital National Center of Gerontology Institute of Geriatric Medicine Chinese Academy of Medical Sciences &amp Peking Union Medical College Beijing China Graduate School of Peking Union Medical College Beijing China Department of Urology Qilu Hospital Shandong University Jinan Shandong China Department of Urology SUN YAT-SEN Memorial Hospital Guangzhou Guangdong China Department of Urology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China Department of Urology Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei China Department of Urology China Rehabilitation Research Center Beijing China Department of Urology West China Hospital Chengdu Sichuan China

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer

引用

Cancer Biology & Medicine 2023年第12期20卷 1047-1059页

作者： Nanhui Chen Zengjun Wang Ming Chen Qi Ma Yi He Yujie Wang Xin Li Mingxing Qiu Lei shi Shaoxing Zhu Qun Xie Xiuheng Liu benkang shi Guowen Lin Weizhong Yang Yongbin Liao Haibin Zhang Shusheng Wang Jiexian Li Shaogang Wang Lijun Dong Hui Chen Jiaju Lu YongyiCheng Xiaoping Zhang Lulin Ma Liqun Zhou He Wang Shen Li Dingwei Ye Department of Urology Meizhou People’s HospitalMeizhou 514089China Department of Urology Jiangsu Province HospitalNanjing 210029China Department of Urology Zhongda Hospital Southeast UniversityNanjing 210009China Translational Research Laboratory for Urology Ningbo First HospitalNingbo 315016China Department of Urology First Affiliated Hospital of JiaxingJiaxing 314050China Department of Urology The First Affiliated Hospital of Xinjiang Medical UniversityUrumqi 830091China Department of Urology Baotou Cancer HospitalBaotou 014016China Department of Urology The People’s Hospital of Sichuan ProvinceChengdu 610032China Department of Urology Yantai Yuhuangding HospitalYantai 264008China Department of Urology Cancer Hospital of The University of Chinese Academy of SciencesHangzhou 310022China Department of Urology Zhuhai Hospital Affiliated with Jinan UniversityZhuhai 519000China Department of Urology Tongji HospitalTongji Medical CollegeHUSTWuhan 430032China Department of Urology Qilu Hospital of Shandong UniversityJinan 250012China Department of Urology Fudan University Shanghai Cancer CenterShanghai 200032China Department of Urology Huizhou Third People’s HospitalHuizhou 516002China Department of Urology Jiangmen Central HospitalJiangmen 529030China Department of Urology Foshan First People’s HospitalFoshan 528041China Department of Urology Guangzhou Province Traditional Chinese Medical HospitalGuangzhou 510120China Department of Urology Guangzhou Panyu Central HospitalGuangzhou 511489China Department of Urology Renmin Hospital of Wuhan UniversityWuhan 430064China Department of Urology Hebei Petro China Central Hospital(China National Petroleum Corporation Central Hospital)Langfang 065099China Department of Urology Harbin Medical University Cancer HospitalHarbin 150086China Department of Urology Shandong Provincial HospitalJinan 250014China Department of Urology Shaanxi Provincial People’s HospitalXi’an 710021China Department of Urology Union Hospital Tongji Medical

Objective:Real-word data on long-acting luteinizing hormone-releasing hormone(LHRH)agonists in Chinese patients with prostate cancer are limited.This study aimed to determine the real-world effectiveness and safety of the LHRH agonist,goserelin,particularly the long-acting 10.8-mg depot formulation,and the follow-up patterns among Chinese prostate cancer patients.Methods:This was a multicenter,prospective,observational study in hormone treatment-na?ve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen.The patients had follow-up evaluations for 26 weeks.The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen(PSA)levels.The secondary outcomes included testosterone and PSA levels,attainment of chemical castration(serum testosterone<50 ng/d L),and goserelin safety.The exploratory outcome was the monitoring pattern for serum testosterone and PSA.All analyses were descriptive.Results:Between September 2017 and December 2019,a total of 294 eligible patients received≥1 dose of goserelin;287 patients(97.6%)were treated with goserelin 10.8-mg depot.At week 24±2,the changes from baseline[standard deviation(95%confidence interval)]in serum testosterone(n=99)and PSA(n=131)were-401.0 ng/d L[308.4 ng/d L(-462.5,-339.5 ng/d L)]and-35.4 ng/m L[104.4 ng/m L(-53.5,-17.4 ng/m L)],respectively.Of 112 evaluable patients,100(90.2%)achieved a serum testosterone level<50 ng/d L.Treatment-emergent adverse events(TEAEs)and severe TEAEs occurred in 37.1%and 10.2%of patients,respectively.The mean testing frequency(standard deviation)was 1.6(1.5)for testosterone and 2.2(1.6)for PSA.Conclusions:Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.

关键词： Goserelin hormone-sensitive luteinizing hormone-releasing hormone prostate cancer China real-world

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

骶神经调控术对神经源性膀胱疗效的Meta分析

引用

现代泌尿外科杂志 2024年第4期29卷 353-358,362页

作者：苏宇航亓文强史本康山东大学齐鲁医院泌尿外科山东济南250012

目的采用Meta分析评价骶神经调控术(SNM)对神经源性膀胱(NB)的疗效,为临床提供关于NB治疗选择的参考。方法通过检索PubMed及知网数据库,收集国内外2010年1月—2022年12月有关SNM治疗NB的文献,按照纳入排除标准筛选文献,并进行质量评价,... 详细信息

目的采用Meta分析评价骶神经调控术(SNM)对神经源性膀胱(NB)的疗效,为临床提供关于NB治疗选择的参考。方法通过检索PubMed及知网数据库,收集国内外2010年1月—2022年12月有关SNM治疗NB的文献,按照纳入排除标准筛选文献,并进行质量评价,提炼数据后采用Review Manager 5.3统计软件进行分析。结果共纳入14项研究、601例患者。Meta分析结果示:SNM对NB患者的排尿次数(WMD=4.30,95%CI:2.84~5.77,P<0.01)、每日尿失禁发作次数(WMD=2.92,95%CI:2.76~3.07,P<0.01)、单次排尿量(WMD=-113.93,95%CI:-159.91~-67.98,P<0.01)、最大尿流率(WMD=-3.23,95%CI:-4.04~-2.42,P<0.01)、残余尿(WMD=111.79,95%CI:79.93~143.64,P<0.01)、最大膀胱容量(WMD=-65.63,95%CI:-84.38~-46.88,P<0.01)以及膀胱顺应性(WMD=-4.65,95%CI:-8.75~-0.55,P=0.03)有显著改善。结论SNM治疗NB的有效性较好,但需要更多随机对照试验的支持。

关键词：骶神经调控术神经源性膀胱下尿路功能障碍下尿路症状排尿次数每日尿失禁发作次数单次排尿量最大尿流率残余尿最大膀胱容量膀胱顺应性

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

一种新型骶神经孔穿刺定位方法的初步确立

引用

现代泌尿外科杂志 2024年第6期29卷 521-526页

作者：徐磊杜飞王文富陈立朋史本康李岩山东大学齐鲁医院泌尿外科山东济南250012

目的通过分析骶神经孔特征,确立一种新型的骶神经穿刺定位方法,帮助临床提高穿刺成功率。方法回顾性分析2019年1月—2022年8月山东大学齐鲁医院158例接受骶神经调控术(SNM)患者的临床资料和骶尾骨计算机断层扫描(CT)三维重建影像,在第3... 详细信息

目的通过分析骶神经孔特征,确立一种新型的骶神经穿刺定位方法,帮助临床提高穿刺成功率。方法回顾性分析2019年1月—2022年8月山东大学齐鲁医院158例接受骶神经调控术(SNM)患者的临床资料和骶尾骨计算机断层扫描(CT)三维重建影像,在第3骶孔水平线测量一侧骶髂关节下缘至同侧第3骶孔内上缘距离(D1)、同侧第3骶孔内上缘至骶中线的水平距离(D2),计算二者比值(D1/D2),用于术中精确定位骶神经孔。分析本组患者的测量数据特点和穿刺结果。结果共纳入患者158例,其中男性89例,女性69例,平均年龄(49.0±16.9)岁,平均D1、D2、D1/D2分别为(29.6±4.9)mm、(13.8±3.2)mm、(2.2±0.6)。相较于男性患者,女性患者的D1[(28.7±4.2)mm vs.(30.7±5.5)mm,P=0.010]及D1/D2均较大[(2.1±0.5)vs.(2.4±0.7),P=0.001]。少年组D1小于成年组[(25.7±5.4)mm vs.(29.8±4.7)mm,P=0.006]。采用本定位方法在术中精确定位后,158例患者均穿刺成功,152例(96.20%)患者术中神经反应应答非常好,2例(1.27%)患者应答良好,4例(2.53%)患者应答一般。结论骶3神经定位点的位置大约位于骶髂关节下缘至骶中线连线中内1/3处。通过X线测量骶髂关节下缘至骶中线的水平距离,并在体表进行骶神经孔定位,有望成为辅助SNM中定位电极置入点的可靠方法。

关键词：脊髓损伤脊髓栓系综合征骶神经调控术体表定位骶髂关节下缘骶神经孔

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial

引用

Chinese Medical Journal 2023年第10期136卷 1207-1215页

作者： Chengyuan Gu Zengjun Wang Tianxin Lin Zhiyu Liu Weiqing Han Xuhui Zhang Chao Liang Hao Liu Yang Yu Zhenzhou Xu Shuang Liu Jingen Wang Linghua Jia Xin Yao Wenfeng Liao Cheng Fu Zhaohui Tan Guohua He Guoxi Zhu Rui Fan Wenzeng Yang Xin Chen Zhizhong Liu Liqiang Zhong benkang shi Degang Ding Shubo Chen Junli Wei Xudong Yao Ming Chen Zhanpeng Lu Qun Xie Zhiquan Hu Yinhuai Wang Hongqian Guo Tiwu Fan Zhaozhao Liang Peng Chen Wei Wang Tao Xu Chunsheng Li Jinchun Xing Hong Liao Dalin He Zhibin Wu Jiandi Yu Zhongwen Feng Mengxiang Yang Qifeng Dou Quan Zeng Yuanwei Li Xin Gou Guangchen Zhou Xiaofeng Wang Rujian Zhu Zhonghua Zhang Bo Zhang Wanlong Tan Xueling Qu Hongliang Sun Tianyi Gan Dingwei Ye Department of Urology Fudan University Shanghai Cancer CenterShanghai 200032China Department of Oncology Shanghai Medical CollegeFudan UniversityShanghai 200032China Department of Urology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029China Department of Urology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdong 510120China Department of Urology The Second Affiliated Hospital of Dalian Medical UniversityDalianLiaoning 116023China Department of Urology The Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityHunan Cancer CenterChangshaHunan 410013China Department of Urology First Hospital of Shanxi Medical UniversityTaiyuanShanxi 030000China Department of Urology Jiangxi Provincial People’s HospitalSchool of MedicineNanchang UniversityNanchangJiangxi 330006China Department of Urology Tianjin Medical University Cancer Institute and HospitalTianjin 300060China Department of Urology Cancer Hospital of China Medical UniversityLiaoning Cancer Hospital and InstituteShenyangLiaoning 110043China Department of Urology Inner Mongolia People’s HospitalHohhotInner Mongolia 010010China Department of Urinary Surgery Taizhou Hospital of Traditional Chinese MedicineTaizhouJiangsu 225300China Department of Urology Linfen People’s HospitalLinfenShanxi 041000China Department of Urology Zhengzhou Central Hospital Affiliated to Zhengzhou UniversityZhengzhouHenan 450006China Department of Urology The Affiliated Hospital of Hebei UniversityBaodingHebei 071000China Department of Urology Chifeng Municipal HospitalChifeng Clinical Medical College of Inner Mongolia Medical UniversityChifengInner Mongolia 024000China Department of Urology Baogang HospitalBaotouInner Mongolia 014010China Department of Oncology The Second People’s Hospital of YibinYibinSichuan 644000China Department of Urology Qilu Hospital of Shandong UniversityJinanShandong 250014China Department of Urology Henan Provincial People’s Hos

Background:LY01005(Goserelin acetate sustained-release microsphere injection)is a modified gonadotropin-releasing hormone(GnRH)agonist injected monthly.This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.Methods:We conducted a randomized controlled,open-label,non-inferiority trial across 49 sites in China.This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections.The primary efficacy endpoints were the percentage of patients with testosterone suppression≤50 ng/dL at day 29 and the cumulative probability of testosterone≤50 ng/dL from day 29 to 85.Non-inferiority was prespecified at a margin of-10%.Secondary endpoints included significant castration(≤20 ng/dL),testosterone surge within 72 h following repeated dosing,and changes in luteinizing hormone,follicle-stimulating hormone,and prostate specific antigen levels.Results:On day 29,in the LY01005 and goserelin implant groups,testosterone concentrations fell below medical-castration levels in 99.3%(142/143)and 100%(140/140)of patients,respectively,with a difference of-0.7%(95%confidence interval[CI],-3.9%to 2.0%)between the two groups.The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3%and 97.8%,respectively,with a between-group difference of 1.5%(95%CI,-1.3%to 4.4%).Both results met the criterion for non-inferiority.Secondary endpoints were similar between groups.Both treatments were well-tolerated.LY01005 was associated with fewer injection-site reactions than the goserelin implant(0%vs.1.4%[2/145]).Conclusion:LY01005 is as effective as goserelin implants in reducing testosterone to castration levels,with a similar safety profile.Trial registration:ClinicalTrials.gov,NCT04563936.

关键词： Prostatic neoplasms LY01005 Gonadotropin-releasing hormone agonist Efficacy Safety

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Consensus on safety management of novel hormonal therapy for advanced prostate cancer

引用

UroPrecision 2023年第2期1卷 53-71,I0005页

作者： Sujun Han Shudong Cheng Degang Ding Jianming Guo Zhisong He Baiye Jin Zhigang Ji Tianxin Lin Yuanjie Niu Weijun Qin benkang shi Jinkai Shao Xi'nan Sheng Qiang Wei Xin Wang Xinghuan Wang Shujie Xia Wanhai Xu Qing Zou Xiongbing Zu Renu Eapen Chi‐Fai Ng Hirotsugu Uemura Hiroji Uemura Cheol Kwak Jae Young Joung Marniza Saad Edmund Chiong Nianzeng Xing National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina The First People's Hospital of Jinzhong JinzhongChina Henan Provincial People's Hospital ZhengzhouChina Zhongshan Hospital Fudan UniversityShanghaiChina Peking University First Hospital BeijingChina The First Affiliated Hospital Zhejiang University School of MedicineHangzhouChina Peking Union Medical College Hospital BeijingChina Sun Yat‐sen Memorial Hospital Sun Yat‐sen UniversityGuangzhouChina The Second Hospital of Tianjin Medical University TianjinChina Xijing Hospital of Air Force Military Medical University Xi'anChina Qilu Hospital of Shandong University JinanChina Shanxi Provincial People's Hospital TaiyuanChina Beijing Cancer Hospital BeijingChina West China Hospital Sichuan UniversityChengduChina Zhongnan Hospital of Wuhan University WuhanChina Shanghai General Hospital ShanghaiChina Fourth Affiliated Hospital of Harbin Medical University HarbinChina Jiangsu Cancer Hospital NanjingChina Xiangya Hospital of Central South University ChangshaChina Peter MacCallum Cancer Centre VictoriaAustralia The Chinese University of Hong Kong Hong KongChina Kindai University Faculty of Medicine Graduate School of Medical Sciences OsakaJapan Yokohama City University Medical Center KanagawaJapan Seoul National University Hospital SeoulKorea National Cancer Center Gyeonggi‐doKorea University of Malaya Medical Centre Wilayah PersekutuanMalaysia National University Hospital SingaporeSingapore

Prostate cancer(PCa)is one of the most prevalent malignant tumors in men,accompanied by high incidence and mortality rates.Novel hormonal therapy(NHT)has emerged as the primary treatment for advanced PCa,providing noticeable clinical benefits.However,the diverse range of adverse events(AEs)associated with NHT may influence both treatment efficacy and patients'quality of life.In light of the latest international clinical research evidence and recommendations from domestic and foreign guidelines,this consensus aims to provide a comprehensive overview of the common AEs experienced during NHT for advanced PCa patients.Additionally,it seeks to develop a hierarchical approach to more efficiently manage AEs,presenting valuable insights for clinical medication and adverse reaction management.

关键词： adverse event novel hormonal therapy prostate cancer safety management

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database

引用

Asian Journal of Urology 2015年第2期2卷 63-69页

作者： Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao benkang shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang Department of Urology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouChina Chinese Bladder Cancer Consortium Department of Urology Renji HospitalShanghai Jiaotong University School of MedicineShanghaiChina Department of Urology Fujian Medical University Union HospitalFuzhouChina Department of Urology General Hospital of Ningxia Medical UniversityYinchuanChina Department of Urology Peking University Third HospitalBeijingChina Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefeiChina Department of Urology The Xinjiang Uygur Autonomous Region People’s HospitalUygurChina Department of Urology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina Department of Urology The First Affiliated Hospital of Guangxi Medical UniversityNanningChina Department of Urology Southwest HospitalThird Military Medical UniversityChongqingChina Department of Urology Daping HospitalThird Military Medical UniversityChongqingChina Department of Urology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina Department of Urology The First Affiliated Hospital of Chongqing Medical UniversityChongqingChina Department of Urology Peking University First HospitalBeijingChina Department of Urology The First Affiliated Hospital of Zhejiang UniversityHangzhouChina Department of Urology China Japan Friendship Hospital of Jilin UniversityChangchunChina Department of Urology Beijing Friendship HospitalCapital Medical UniversityBeijingChina Department of Urology Wuhan General Hospital of Guangzhou MilitaryWuhanChina Department of Urology The First Affiliated Hospital of Shanxi UniversityTaiyuanChina Department of Urology Qilu Hospital of Shandong UniversityJinanChina Department of Urology West China HospitalSichuan UniversityChengduChina Department of Urology The Second Affiliated Hospital of Tianjin Medical UniversityTianjinChina Department of Urology Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China.

关键词： Bladder cancer Diagnosis Treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

膀胱过度活动症的诊断及治疗进展

引用

山东大学学报（医学版） 2018年第3期56卷 1-5,11页

作者：史本康山东大学齐鲁医院泌尿外科山东济南250012

膀胱过度活动症(OAB)是泌尿外科常见疾病,以尿急症状为主要表现,多数患者伴有尿频症状,有或没有急迫性尿失禁表现。OAB虽然对患者寿命无明显影响,但尿急尿频症状严重降低患者生活质量,给患者及社会造成沉重的经济负担。对OAB的定义、流... 详细信息

膀胱过度活动症(OAB)是泌尿外科常见疾病,以尿急症状为主要表现,多数患者伴有尿频症状,有或没有急迫性尿失禁表现。OAB虽然对患者寿命无明显影响,但尿急尿频症状严重降低患者生活质量,给患者及社会造成沉重的经济负担。对OAB的定义、流行病学、病因及发病机制、诊断评估和治疗等内容做综述。

关键词：膀胱过度活动症逼尿肌内注射肉毒素骶神经电刺激胫神经电刺激

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

前列腺增生微创手术方式在中国患者中的应用选择

引用

临床泌尿外科杂志 2023年第10期38卷 725-728页

作者：史本康李岩杜飞山东大学齐鲁医院泌尿外科济南250012

良性前列腺增生是老年男性患者常见的良性疾病,对于药物等保守治疗效果不佳的患者,前列腺微创手术是治疗良性前列腺增生的有效方式。随着医疗技术的进展,微创手术方式越来越多,包括经尿道前列腺电切术、经尿道前列腺激光手术、前列腺热... 详细信息

良性前列腺增生是老年男性患者常见的良性疾病,对于药物等保守治疗效果不佳的患者,前列腺微创手术是治疗良性前列腺增生的有效方式。随着医疗技术的进展,微创手术方式越来越多,包括经尿道前列腺电切术、经尿道前列腺激光手术、前列腺热蒸汽消融术、前列腺动脉栓塞术、前列腺支架置入术等多种手术方式。本文对前列腺增生微创手术进行总结,尤其是对于中国前列腺增生患者目前可选择的治疗方式进行了总结和评述。

关键词：前列腺增生微创手术

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population

引用

Asian Journal of Urology 2019年第1期6卷 114-121页

作者： Liqun Zhou Kaiwei Yang Xuesong Li Yi Ding Dawei Mu Hanzhong Li Yong Yan Jinyi Li Dongwen Wang Wei Li Yulong Cong Jiangping Gao Kewei Ma Yajun Xiao Sheng Zhang Hongyi Jiang Weilie Hu Qiang Wei Xunbo Jin Zhichen Guan Qingyong Liu Danfeng Xu Xin Gao Yongguang Jiang Weimin Gan Guang Sun Qing Wang Yanhui Liu Jianquan Hou Liping Xie Xishuang Song Fengshuo Jin Jiafu Feng Ming Cai Zhaozhao Liang Jie Zhang Dingwei Ye Lin Qi Lulin Ma Jianzhong Shou Yuping Dai Jianyong Shao Ye Tian shizhe Hong Tao Xu Chuize Kong Zefeng Kang Yuexin Liu Xun Qu benkang shi Shaobin Zheng Yi Lin Shujie Xia Dong Wei Jianbo Wu Weiling Fu Zhiping Wang Jianbo Liang Department of Urology Peking University First HospitalBeijingChina Institute of Urology Peking UniversityBeijingChina National Urological Cancer Center BeijingChina Air Force General Hospital PLABeijingChina Department of Urology Peking Union Medical College HospitalBeijingChina Department of Urology Beijing Chao-Yang HospitalBeijingChina Department of Urology Armed-Police General HospitalBeijingChina Department of Urology Shanxi Medical University First HospitalTaiyuanChina Department of Urology Hebei Medical University Second HospitalShijiazhuangChina Department of Urology The General Hospital of the People’s Liberation ArmyBeijingChina Department of Urology First Affiliated Hospital of Jilin UniversityChangchunChina Department of Urology Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina Department of Pathology The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina Department of Urology The Second Xiangya Hospital of Central South UniversityChangshaChina Department of Urology General Hospital of Guangzhou Military Command of PLAGuangzhouChina Department of Urology West China School of MedicineChengduChina Department of Urology Shangdong Province-owned HospitalJinanChina Department of Urology Peking University Shenzhen HospitalShenzhenChina Department of Urology The Central Hospital of Jinan CityJinanChina Department of Urology Shanghai Changzheng HospitalShanghaiChina Department of Urology The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina Department of Urology Beijing Anzhen Hospital of Capital Medical UniversityBeijingChina Department of Urology The Second Affiliated Hospital of Xi’an Jiaotong UniversityXi’anChina Department of Urology The Second Hospital of Tianjin Medical UniversityTianjinChina Department of Urology People’s Hospital of Xinjiang Uygur Autonomous RegionWulumuqiChina Department of Urology Guangdong General HospitalGuangzhouChina Department of Urology The First Affil

Objective:To evaluate the diagnostic value of fluorescence in situ hybridization(FISH)in bladder cancer.Methods:We enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December 2008.Receiver operating characteristic(ROC)curve analysis was performed and the area under curve(AUC)values were calculated for both the FISH and urine cytology tests.Results:A cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population.A total of 4807 patients with hematuria were prospectively,randomly enrolled for the simultaneous analysis of urine cytology,FISH testing,and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised specimen.Overall,the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%,while that of cytology was 33.4%(p<0.001).The sensitivity values of FISH for non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7%and 89.6%,respectively(p=0.004).The sensitivity values of FISH for low and high grade bladder cancer were 82.6%and 90.1%,respectively(p=0.002).Conclusion:FISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and stages.Higher sensitivity using FISH was obtained in high grade and muscle invasive tumors.

关键词： Bladder transitionalcell carcinoma Fluorescence in situ hybridization Detection Grade Stage

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：